Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediPharm LabsSTU:MLZ -1.09% Debt-to-Equity is 0.01 as of Jun. 2026, which is 50% below its 10-year median of 0.02. The stock has 4 warning signs investors should review. Among 811 Drug Manufacturers companies, MediPharm Labs ranks better than 99.88% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for MediPharm Labs's Debt-to-Equity or its related term are showing as below:
STU:MLZ'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.3
Current: 0.01
During the past 9 years, the highest Debt-to-Equity Ratio of MediPharm Labs was 0.30. The lowest was 0.00. And the median was 0.02.
STU:MLZ's Debt-to-Equity is ranked better than 99.88% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs STU:MLZ: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
MediPharm Labs Debt-to-Equity Related Terms
MediPharm Labs Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for MediPharm Labs's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediPharm Labs (STU:MLZ) has a Debt-to-Equity of 0.01 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MediPharm Labs and its competitors. This is 50% below median its historical median of 0.02. According to the industry distribution chart, MediPharm Labs ranks #1 out of 811 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is MediPharm Labs' Debt-to-Equity too high?
MediPharm Labs' current Debt-to-Equity of 0.01 is 50% below median its 10-year median of 0.02. The Drug Manufacturers industry median Debt-to-Equity is 0.27. MediPharm Labs' value of 0.01 is 96.3% below this industry median. Based on the distribution chart, MediPharm Labs ranks #1 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does MediPharm Labs' Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #1 out of 811 companies for Debt-to-Equity. This places MediPharm Labs in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. MediPharm Labs' value of 0.01 is 96.3% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.27, MediPharm Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediPharm Labs's current Debt-to-Equity of 0.01 is 96.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MediPharm Labs and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediPharm Labs's current Debt-to-Equity is 0.01, which is 50% below median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (STU:MLZ) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.05 — trading 13.8% above its estimated fair value. The current Debt-to-Equity is 0.01, which is 50% below median its 10-year median of 0.02 and 96.3% below the Drug Manufacturers industry median of 0.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For MediPharm Labs (STU:MLZ), the current Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MLZ has been successfully added to your 
